Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Xeris Biopharma Holdings Inc shares valued at $10,147 were purchased by Schmid John P. on Aug 12 ’24. At $2.25 per share, Schmid John P. acquired 4,515 shares. The insider’s holdings grew to 25,200 shares worth approximately $87444.0 following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Schmid John P. purchased 4,285 shares, netting a total of over 10,134 in proceeds. Following the buying of shares at $2.37 each, the insider now holds 20,685 shares.
Before that, Schmid John P. had added 5,400 shares to its account. In a trade valued at $10,314, the Director bought Xeris Biopharma Holdings Inc shares for $1.91 each. Upon closing the transaction, the insider’s holdings increased to 5,400 shares, worth approximately $56908.0.
As published in a research note from Piper Sandler on November 11, 2024, Xeris Biopharma Holdings Inc [XERS] has been rated down from an Overweight to a Neutral and the price target has been revised to $3. Analysts at Oppenheimer started covering the stock with ‘”an Outperform”‘ outlook in a report released in late March. As of August 28, 2023, Craig Hallum has initiated its “Buy” rating for XERS. Earlier on October 21, 2022, Jefferies initiated its rating. Their recommendation was “a Buy” for XERS stock.
Analyzing XERS Stock Performance
During the last five days, there has been a surge of approximately 1.76%. Over the course of the year, Xeris Biopharma Holdings Inc shares have jumped approximately 47.66%. Shares of the company reached a 52-week high of $3.87 on 12/06/24 and a 52-week low of $1.69 on 04/26/24. A 50-day SMA is recorded $3.26, while a 200-day SMA reached $2.56. Nevertheless, trading volume fell to 0.52 million shares from 1.22 million shares the previous day.
Support And Resistance Levels for Xeris Biopharma Holdings Inc (XERS)
According to the 24-hour chart, there is a support level at 3.41, which, if violated, would cause prices to drop to 3.36. In the upper region, resistance lies at 3.52. The next price resistance is at 3.58. RSI (Relative Strength Index) is 54.75 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.01, which suggests the price will decrease in the coming days. Percent R is at 57.14%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
